BTG Plc has exceeded a forecast issued as recently as April and reported revenue of £197 million for the year ended 31 March, up by 77% a year earlier. Revenue was boosted by strong sales of the antibody- fragment treatments, CroFab and DigiFab. ---Subscribe to MedNous to access this article--- Company News
